Marker Therapeutics Inc Cash Flow Conversion Efficiency
Marker Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Marker Therapeutics Inc (MRKR) has a cash flow conversion efficiency ratio of -0.305x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.72 Million) by net assets ($12.17 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Marker Therapeutics Inc (1999–2025)
Cash flow conversion efficiency of Marker Therapeutics Inc from 1999 to 2025. This chart illustrates how Marker Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Marker Therapeutics Inc stock price today for real-time trading data and today's change.
Marker Therapeutics Inc Cash Flow Conversion Ratio Explained
Marker Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Marker Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Marker Therapeutics Inc ranked by their cash flow conversion efficiency. Also see MRKR market cap overview for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Metalliance SA
PA:MLETA
|
N/A |
|
Bina Darulaman Bhd
KLSE:6173
|
-0.031x |
|
Communication Cable Systems Indonesia Tbk PT
JK:CCSI
|
0.050x |
|
REMAK SA
WAR:RMK
|
0.044x |
|
A Rank Bhd
KLSE:7214
|
-0.039x |
|
LQwD FinTech Corp
V:LQWD
|
-0.021x |
|
Denge Yatirim Holding AS
IS:DENGE
|
-0.187x |
|
Kodi-S Co Ltd
KQ:080530
|
-0.029x |
Annual Cash Flow Conversion Efficiency for Marker Therapeutics Inc (1999–2025)
The table below shows the annual cash flow conversion efficiency of Marker Therapeutics Inc from 1999 to 2025. Review Marker Therapeutics Inc (MRKR) free cash flow to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $16.80 Million | $-12.01 Million | -0.715x | -21.67% |
| 2024-12-31 | $18.56 Million | $-10.91 Million | -0.588x | +49.75% |
| 2023-12-31 | $14.05 Million | $-16.44 Million | -1.170x | +14.98% |
| 2022-12-31 | $19.60 Million | $-26.97 Million | -1.376x | -121.87% |
| 2021-12-31 | $43.99 Million | $-27.28 Million | -0.620x | +15.35% |
| 2020-12-31 | $27.34 Million | $-20.03 Million | -0.733x | -76.66% |
| 2019-12-31 | $44.09 Million | $-18.28 Million | -0.415x | -69.97% |
| 2018-12-31 | $59.34 Million | $-14.48 Million | -0.244x | +89.42% |
| 2017-12-31 | $3.66 Million | $-8.44 Million | -2.307x | -119.17% |
| 2016-12-31 | $6.18 Million | $-6.51 Million | -1.053x | -617.66% |
| 2015-12-31 | $-21.36 Million | $-4.34 Million | 0.203x | -90.48% |
| 2014-12-31 | $-1.02 Million | $-2.19 Million | 2.137x | +2597.17% |
| 2013-12-31 | $-8.77 Million | $-694.58K | 0.079x | -71.32% |
| 2012-12-31 | $-5.67 Million | $-1.57 Million | 0.276x | -27.04% |
| 2011-12-31 | $-3.46 Million | $-1.31 Million | 0.379x | +33.91% |
| 2010-12-31 | $-3.27 Million | $-925.04K | 0.283x | -84.14% |
| 2009-12-31 | $-629.39K | $-1.12 Million | 1.782x | +654.23% |
| 2008-12-31 | $-3.02 Million | $-714.42K | 0.236x | -67.71% |
| 2007-12-31 | $-1.67 Million | $-1.23 Million | 0.732x | +85.14% |
| 2006-12-31 | $-3.00 Million | $-1.19 Million | 0.395x | -24.67% |
| 2005-12-31 | $-2.22 Million | $-1.16 Million | 0.525x | +5.38% |
| 2004-12-31 | $-2.44 Million | $-1.21 Million | 0.498x | -87.63% |
| 2003-12-31 | $-643.75K | $-2.59 Million | 4.026x | +233.30% |
| 2002-12-31 | $465.83K | $-1.41 Million | -3.020x | -292.90% |
| 2000-12-31 | $-561.95K | $-879.74K | 1.566x | -72.84% |
| 1999-12-31 | $-141.42K | $-815.18K | 5.764x | -- |
About Marker Therapeutics Inc
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. The company's multi antigen recognizing (MAR)-T cell therapy technology is based on the selective expansion of non-engineered tumor-specific T cells that recognize tumor-assoc… Read more